
Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

Sygnature Discovery Ltd acquires leading Canadian CRO
The purchase of NuChem Sciences for an undisclosed sum is the third in a series of acquisitions in sixteen months as part of Sygnature's global...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

EU Regulation of Genome Editing in Plants – not yet a law
The EU proposal has a clear message: the requirements for simple genome-edited plants shall be significantly relaxed. There will no longer be the...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...